ArticleJournal of Cancer2019

Blocking the PD-1/PD-L1 axis in dendritic cell-stimulated Cytokine-Induced Killer Cells with pembrolizumab enhances their therapeutic effects against hepatocellular carcinoma.

Wan Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.